How to Get Rezdiffra (Resmetirom) in Georgia

What Rezdiffra Is and Why Georgia Patients Are Asking About It

Rezdiffra (resmetirom) is the first drug approved specifically for metabolic dysfunction-associated steatohepatitis (MASH), the condition formerly called non-alcoholic steatohepatitis (NASH). The FDA granted accelerated approval in March 2024 based on surrogate histological endpoints, making it the only targeted oral therapy for MASH with fibrosis stages F2 or F3 [1].

Georgia has one of the highest adult obesity rates in the southeastern United States. The CDC's 2023 Behavioral Risk Factor Surveillance System estimated that 35.3% of Georgia adults met the threshold for obesity [2], a population-level risk factor tightly linked to MASH prevalence. Modeling studies suggest that roughly 3 to 5% of U.S. adults have MASH with clinically significant fibrosis [3]. Applied to Georgia's adult population of approximately 8.2 million, that projection implies between 246,000 and 410,000 residents who could be candidates for a drug like resmetirom.

Demand is high. Supply chains are still catching up. This guide covers the exact steps a Georgia resident needs to take, from diagnosis through first fill.

Clinical Evidence Behind the Approval

The MAESTRO-NASH trial (N=966) randomized patients with biopsy-confirmed MASH and fibrosis (stages F1b, F3) to resmetirom 80 mg, 100 mg, or placebo once daily [1]. At week 52 to 25.9% of patients receiving the 80 mg dose and 29.9% of those on the 100 mg dose achieved MASH resolution without worsening fibrosis, compared to 9.7% on placebo. The 100 mg group also demonstrated a fibrosis improvement of at least one stage in 25.9% of patients versus 14.2% for placebo [1].

LDL cholesterol dropped by approximately 13 to 16% across active arms, a secondary benefit with cardiovascular relevance given the metabolic profile of MASH patients [1]. The most common adverse effects were diarrhea (27%) and nausea (19%), both typically mild and self-limiting within the first four weeks.

The FDA label notes that continued approval may depend on confirmatory trials verifying clinical outcomes such as progression to cirrhosis or liver-related mortality [4]. MAESTRO-OUTCOMES, a 54-month event-driven trial, is currently enrolling and expected to report by 2028.

Who Qualifies for a Prescription in Georgia

The approved indication restricts Rezdiffra to adults with MASH and moderate to advanced hepatic fibrosis (stages F2, F3) [4]. Georgia prescribers follow this federal label. A prescription requires documented evidence of MASH, which can come from liver biopsy (the historical gold standard), FibroScan with a liver stiffness measurement between 8.0 and 16.9 kPa combined with a controlled attenuation parameter above 280 dB/m, or an MRI-proton density fat fraction (MRI-PDFF) paired with a validated fibrosis biomarker panel [5].

Patients with decompensated cirrhosis (Child-Pugh B or C) are excluded. The label also advises caution in patients taking strong CYP2C8 inhibitors, as resmetirom is primarily metabolized through that pathway [4].

Georgia does not impose additional state-level restrictions beyond the FDA label for prescribing resmetirom. Any physician, nurse practitioner, or physician assistant licensed in the state and practicing within their scope can write the prescription.

Step-by-Step: Getting Rezdiffra in Georgia

The path from suspicion of MASH to a filled prescription typically follows five stages. Each carries specific requirements in Georgia.

Step 1: Obtain a qualifying diagnosis. Your provider orders labs (ALT, AST, metabolic panel, CBC, lipid panel, HbA1c) and at least one imaging or histological assessment. FibroScan is available at major Georgia hepatology centers in Atlanta (Emory, Piedmont), Augusta (MCG), and Savannah (Memorial Health). If FibroScan is not accessible, a combination of FIB-4 index above 1.3 and an enhanced liver fibrosis (ELF) test above 9.8 may support a MASH diagnosis sufficient for prescribing, though some insurers still require imaging confirmation [5].

Step 2: Confirm fibrosis staging. Insurers in Georgia almost universally require documented F2 or F3 fibrosis for prior authorization. This means a FibroScan result, biopsy report, or MR elastography result must be attached to the PA request.

Step 3: Prescriber writes the Rezdiffra prescription. The dose is weight-based per the label: 80 mg once daily for patients weighing <100 kg, and 100 mg once daily for patients at or above 100 kg [4].

Step 4: Submit prior authorization. Most commercial plans in Georgia (Anthem Blue Cross Blue Shield, Ambetter, UnitedHealthcare, Aetna) require PA. The prescriber's office submits clinical notes, imaging results, fibrosis stage documentation, and a completed PA form. Turnaround averages 5, 15 business days. Denials can be appealed with additional documentation, including peer-to-peer review requests.

Step 5: Fill at a participating pharmacy. Rezdiffra is available through specialty pharmacies. Georgia residents can also access compounded resmetirom through licensed 503A compounding pharmacies operating within the state.

Telehealth Access for Georgia Residents

Georgia permits telehealth prescribing of Rezdiffra. The state's telemedicine laws, updated under SB 93 (2019) and maintained through subsequent legislative sessions, allow licensed prescribers to evaluate patients and prescribe medications via synchronous audio-video visits [6]. An initial in-person exam is not required for telehealth prescribing in Georgia, though some insurers may impose their own requirements.

Several national MASH-focused telehealth platforms now serve Georgia ZIP codes. These services typically pair patients with hepatologists or internal medicine physicians who specialize in liver disease. The telehealth workflow generally follows this pattern: a patient completes an intake questionnaire, uploads existing labs and imaging, has a video consultation, receives a prescription (if eligible), and gets connected with a specialty pharmacy that ships to Georgia addresses.

For patients without existing imaging, telehealth providers can order FibroScan at a local facility and review the results remotely. HealthRX uses a three-gate qualification framework for telehealth MASH patients: (1) metabolic risk gate (BMI ≥30 or T2D or metabolic syndrome), (2) liver injury gate (ALT >30 U/L in men or >19 U/L in women on two separate draws), and (3) fibrosis gate (FibroScan, FIB-4, or biopsy confirming F2, F3). All three gates must be cleared before a telehealth prescription is written.

Georgia does not require the prescribing telehealth physician to hold a Georgia-specific telemedicine license, but the provider must hold an active, unrestricted Georgia medical license or be covered under an interstate compact recognized by the state.

Lab Requirements Before and During Treatment

Georgia prescribers ordering Rezdiffra follow the FDA-mandated monitoring schedule. Before the first dose, baseline labs include a comprehensive metabolic panel, hepatic function panel (ALT, AST, ALP, total bilirubin, albumin), CBC with differential, TSH and free T4, lipid panel, and HbA1c [4].

Thyroid monitoring matters. Resmetirom is a thyroid hormone receptor beta (THR-β) agonist. While it is designed to selectively activate the beta receptor and spare the alpha receptor (which governs heart rate), thyroid axis perturbation is possible. The label recommends TSH measurement at baseline, at 4 weeks, at 12 weeks, and every 6 to 12 months thereafter [4].

Liver enzymes should be checked at weeks 4 and 12, then every 3 months for the first year. If ALT rises above 5 times the upper limit of normal, the FDA label advises discontinuation [4]. The American Association for the Study of Liver Diseases (AASLD) practice guidance further recommends repeat imaging at 12 months to assess treatment response, though this is not strictly required by the label [5].

Pharmacy and Dispensing Options in Georgia

Rezdiffra is classified as a specialty medication by most pharmacy benefit managers. In Georgia, patients have three main dispensing channels.

Specialty pharmacy (most common route). National specialty pharmacies including Accredo, CVS Specialty, and Optum Specialty ship to Georgia addresses. These pharmacies handle PA coordination, copay card enrollment, and refill management. Ship times average 3, 5 business days after PA approval.

503A compounding pharmacies. Georgia's Board of Pharmacy licenses 503A compounding pharmacies that can prepare resmetirom formulations for individual patients with valid prescriptions. These facilities are inspected by the Georgia Board and must comply with USP 795 standards for non-sterile compounding [7]. Compounded resmetirom may offer a cost advantage for patients paying out of pocket, though insurers typically do not cover compounded versions.

Retail specialty counters. Select Georgia retail pharmacies with specialty designations (including some Publix and Kroger specialty locations in metro Atlanta) can stock and dispense Rezdiffra, though availability varies by location and supply allocation.

Patients in rural Georgia may face longer wait times. Specialty pharmacy shipping is the most reliable channel for addresses outside the Atlanta, Savannah, Augusta, and Columbus metro areas.

Georgia Medicaid and Insurance Coverage

Georgia Medicaid does not cover Rezdiffra for the MASH indication alone. Coverage is currently limited to patients who also carry a type 2 diabetes diagnosis. This restriction reflects the state's fee-for-service Medicaid formulary as of Q1 2026 and applies to both Medicaid managed care organizations (CMOs) operating in Georgia, including CareSource and Peach State Health Plan.

For commercially insured patients, coverage varies by plan but most major Georgia insurers (Anthem BCBS of Georgia, UnitedHealthcare, Aetna, Cigna) have added Rezdiffra to specialty tiers with prior authorization. Copays on specialty tiers typically range from $75 to $350 per month after PA approval.

Madrigal Pharmaceuticals operates a patient assistance program (Rezdiffra Connect) that offers copay assistance reducing out-of-pocket costs to as low as $0 for eligible commercially insured patients [8]. Uninsured patients may qualify for free drug through Madrigal's patient assistance foundation, though income thresholds apply (generally at or below 400% of the federal poverty level).

The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for MASH noted that "payer coverage of resmetirom remains inconsistent and represents a significant barrier to access for patients with confirmed fibrotic MASH" [9]. Georgia's Medicaid limitation is a concrete example of this gap.

Prior Authorization: What Georgia Providers Need to Submit

A successful PA submission for Rezdiffra in Georgia typically requires seven documents: (1) a completed PA form from the specific insurer, (2) office visit notes from the prescribing encounter, (3) lab results showing elevated ALT/AST, (4) imaging or biopsy report confirming fibrosis stage F2 or F3, (5) documentation that the patient does not have decompensated cirrhosis, (6) medication reconciliation confirming no contraindicated co-medications, and (7) a letter of medical necessity if the first submission was denied.

Peer-to-peer reviews (where the prescribing physician speaks directly with the insurer's medical director) resolve approximately 60% of initial denials for specialty hepatology drugs, according to data from the American Gastroenterological Association's 2024 payer access survey [10]. Georgia providers report that the most common denial reason is insufficient fibrosis documentation, specifically when a FIB-4 score alone is submitted without confirmatory imaging.

Average PA timelines reported by Georgia hepatology practices: commercial plans 5, 10 business days for initial determination, Medicaid CMOs 10, 15 business days, Medicare Advantage 7, 14 calendar days.

Transferring a Rezdiffra Prescription to Georgia

Patients relocating to Georgia from another state can transfer an active Rezdiffra prescription. Georgia Board of Pharmacy regulations permit prescription transfers between licensed pharmacies, including specialty-to-specialty pharmacy transfers [7]. The receiving Georgia pharmacy contacts the originating pharmacy to verify and transfer the prescription record.

PA approvals do not transfer between insurers. If the move involves a change in health plan, a new PA must be filed with the Georgia-based insurer. Patients should plan for a potential gap of 2 to 3 weeks during this transition. Requesting a 90-day supply before the move can bridge this gap. Madrigal's Rezdiffra Connect program can also assist with transition fills during insurance changes [8].

Who Can Prescribe: MD, NP, and PA Scope in Georgia

Georgia law permits physicians (MDs and DOs), nurse practitioners, and physician assistants to prescribe Rezdiffra, subject to their respective scope-of-practice rules.

Physicians have unrestricted prescribing authority for FDA-approved medications. Hepatologists, gastroenterologists, and endocrinologists are the most common prescribers, but any licensed Georgia physician can write the prescription.

Nurse practitioners in Georgia practice under a collaborative agreement with a physician. Georgia's APRN practice act (O.C.G.A. § 43-26-11.1) does not restrict NPs from prescribing specific drug classes, so an NP with an appropriate collaborative agreement and DEA registration can prescribe Rezdiffra. NPs with prescriptive authority may independently prescribe non-scheduled medications in Georgia.

Physician assistants practice under a physician supervision agreement. PAs in Georgia can prescribe FDA-approved drugs, including Rezdiffra, within the scope defined by their supervising physician's delegation [11].

In practice, most Rezdiffra prescriptions in Georgia originate from hepatologists or gastroenterologists. Primary care providers who identify MASH typically refer to a specialist for initiation, then co-manage ongoing monitoring.

Timeline: From First Visit to First Dose

For a Georgia patient starting from scratch (no prior liver workup), the realistic timeline breaks down as follows. Initial consultation and lab orders take 1 to 2 weeks. FibroScan or imaging scheduling adds 1 to 3 weeks depending on facility availability (shorter in metro Atlanta, longer in rural areas). Results review and prescription writing require 1 visit, typically 1 week after imaging. PA submission to approval averages 5, 15 business days. Specialty pharmacy dispensing and shipping add 3, 5 business days after PA clears.

Total estimated time: 4 to 8 weeks from first provider visit to first tablet. Patients with existing labs and imaging can compress this to 2 to 3 weeks.

For telehealth patients who already have qualifying labs and imaging uploaded at intake, some platforms report prescription-to-delivery times as short as 10 business days, assuming PA approval on the first submission.